1. Generics Bulletin
  2. >>Business
  3. >>Deals

Ipca Adds To API Business By Acquiring Ramdev

 
• By Penelope MacRae

India’s Ipca is boosting its API business with a deal to acquire local firm Ramdev Chemical for INR1.1bn in cash.

DigitalGraph
Ipca’s deal will expand its API business and help it target global markets • Source: Shutterstock

India’s Ipca Laboratories has announced its third acquisition in two years with a deal to buy manufacturer Ramdev Chemical Ltd for INR1.1bn ($15.7mn). Ipca said the acquisition would allow the company to “grow its active pharmaceutical ingredient (API) business by adding new molecules in its products basket, with the possibility of forward-integrating such products in its dosage formulations business for the world market.”

Ipca will purchase 100% of shares in Ramdev, which is based in the Palghar district of the western Indian state of Maharashtra. The firm employs 170 staff and manufactures and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Abiogen And mAbxience Join Forces In Italy

 
• By Dave Wallace

Spanish biosimilars developer mAbxience has struck a deal with Italy’s Abiogen covering an undisclosed biosimilar for the Italian market.

Teva Brings In European Trastuzumab With Prestige BioPharma Agreement

 
• By Dean Rudge

Teva will now market biosimilar Herceptin in both the US and Europe, after penning an agreement with Singaporean firm Prestige BioPharma for its Tuznue rival to the monoclonal antibody to treat HER2-positive breast cancer and HER2-positive metastatic stomach cancer.

SteinCares Deal Leads Lupin’s Ranibizumab Into Latin America

 
• By Dave Wallace

Lupin is planning to make inroads into the Latin American biosimilars market through a deal with local player SteinCares for a ranibizumab rival to Lucentis.

Advanz Allies With Pharmathen On Long-Acting Injectable

 
• By Dave Wallace

Advanz Pharma has announced details of a fresh alliance on long-acting injectables with Pharmathen.

More from Business

SteinCares Deal Leads Lupin’s Ranibizumab Into Latin America

 
• By Dave Wallace

Lupin is planning to make inroads into the Latin American biosimilars market through a deal with local player SteinCares for a ranibizumab rival to Lucentis.

Hikma Gears Up To Enter US Biosimilars Market With Ustekinumab Nod

 
• By Dave Wallace

Hikma is set to make its first launch into the competitive US biosimilars market after its Bio-Thera-partnered Stelara rival, Starjemza, was approved by the FDA.

Advanz Allies With Pharmathen On Long-Acting Injectable

 
• By Dave Wallace

Advanz Pharma has announced details of a fresh alliance on long-acting injectables with Pharmathen.